Novo Nordisk and Inversago Pharma have announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion dollars in cash.  (Source: © Martin Nordmark)
Business Strategy

Novo Nordisk to Takeover Inversago Pharma

Novo Nordisk has plans to acquire Inversago Pharma, a developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The 1.075-billion-dollar acquisition includes Inversago Pharma’s lead development asset INV-202, an oral CB1 inverse agonist.

Read on